Cleared Traditional

K122370 - CONTOUR NEXT LINK WIRELESS BLOOD GLUCOSE MONITOR

K122370 is an FDA 510(k) clearance for CONTOUR NEXT LINK WIRELESS BLOOD GLUCOS..., manufactured by Bayer Healthcare. The device is a Class 2 Chemistry device with product code NBW cleared through the Traditional 510(k) pathway after a 416-day FDA review.

K122370 · Bayer Healthcare · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2013
Decision
416d
Days
Class 2
Risk

K122370 is an FDA 510(k) clearance for the CONTOUR NEXT LINK WIRELESS BLOOD GLUCOSE MONITOR. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Bayer Healthcare (Mishawaka, US). The FDA issued a Cleared decision on September 26, 2013 after a review of 416 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Bayer Healthcare devices

FDA 510(k) Submission Details - K122370

510(k) Number K122370 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 06, 2012
Decision Date September 26, 2013
Days to Decision 416 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
328d slower than avg
Panel avg: 88d · This submission: 416d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 424
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K122370.
DA01 BLOOD GLUCOSE MONITORING SYSTEM
K132338 · Delbio Incorporation · Oct 2013
FOCUS BLOOD GLUCOSE MONITORING SYSTEM, FOCUS PRO BLOOD GLUCOSE MONITORING SYSTEM
K131013 · Nova Biomedical Corporation · Oct 2013
GLOOKO DEVICE SYSTEM FOR GLOOKO APPLICATION
K132272 · Glooko, Inc. · Oct 2013
ONETOUCH VERIO BLOOD GLUCOSE MONITORING SYSTEM
K131363 · Cilag GmbH International · Aug 2013
DIATRUE PLUS BLOOD GLUCOSE MONITORING SYSTEM
K130244 · Delbio Incorporation · Aug 2013
CARESENS N LINK BLOOD GLUCOSE MONITORING SYSTEM
K130696 · I-Sens, Inc. · Aug 2013